SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Raimondi, S. C. Articles by Carroll, A. J. Search for Related Content PubMed PubMed Citation Articles by Raimondi, S. C. Articles by Carroll, A. J. Related Collections Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 94 No. 11 (December 1), 1999: pp. 3707-3716 Chromosomal Abnormalities in 478 Children With Acute Myeloid Leukemia: Clinical Characteristics and Treatment Outcome in a Cooperative Pediatric Oncology Group StudyPOG 8821 Susana C. Raimondi, Myron N. Chang, Yaddanapudi Ravindranath, Frederick G. Behm, Mary V. Gresik, C. Philip Steuber, Howard J. Weinstein, and Andrew J. Carroll for the Pediatric Oncology Group From the Departments of Pathology and Laboratory Medicine, St Jude Children's Research Hospital, and University of Tennessee, Memphis, TN; Children's Hospital of Michigan, Barbara Ann Karmanos Cancer Institute, and Wayne State University, Detroit, MI; POG Statistical Office and the Department of Statistics, The University of Florida, Gainesville, FL; Baylor College of Medicine, Texas Children's Hospital, Houston, TX; Harvard Medical School and Massachusetts General Hospital, Boston, MA; and University of Alabama at Birmingham, Birmingham, AL. We determined the type and frequency of chromosomal aberrations in leukemic cells of 478 children diagnosed with acute myeloid leukemia and enrolled in the Pediatric Oncology Group study 8821. Of the 478 cases, 109 (22.8%) had normal karyotypes. Chromosomal abnormalities of 280 patients (58.6%) were classified into subgroups: 11q23 abnormalities (n = 88, 18.4%), t(8;21) (n = 56, 11.7%), t(15;17) (n = 55, 11.5%), inv(16)/t(16;16) (n = 28, 5.9%), trisomy 8 alone (n = 10, 2.1%), monosomy 7 (n = 9, 1.9%), non-Down-associated trisomy 21 alone (n = 7, 1.5%), and rare recurrent chromosomal translocations (n = 27, 5.6%). The remaining 89 patients (18.6%) had miscellaneous clonal abnormalities. Overall, 84.9% of the children achieved a complete remission; the 4-year event-free survival (EFS) estimate was 33.8% ± 2.4%. Remission rates were significantly higher (96.4%, P = .011) for patients with t(8;21) and inv(16)/t(16;16) but significantly lower (74.5%, P = .022) for those with t(15;17). The 4-year survival rate for all patients was 43.5% ± 2.4%; for those with an inv(16)/t(16;16), 75.0% ± 8.6%; a normal karyotype, 53.8% ± 4.9%; a t(8;21), 51.6% ± 7.3%; a t(15;17), 39.8% ± 6.9%; and an 11q23 abnormality, 32.9% ± 5.1%. Four-year EFS estimates for patients with inv(16)/t(16;16) (58.2% ± 10.9%, P = .007), t(8;21) (45.1% ± 7.7%, P = .014), or normal karyotypes (43.1% ± 5.0%, P = .012) were higher than the 4-year EFS estimate for all patients, but EFS estimates for patients with t(15;17) (19.6% ± 8.0%, P = .033) or 11q23 abnormalities (23.8% ± 4.8%, P = .0013) were lower. EFS estimates did not differ significantly among 11q23 subgroups. Limited analysis suggested that patients with inv(16) can be salvaged better following relapse than those with t(8;21). Thus, patients with an inv(16)/t(16;16) may have high survival rates when treated with chemotherapy alone. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: B. V. Balgobind, P. Van Vlierberghe, A. M. W. van den Ouweland, H. B. Beverloo, J. N. R. Terlouw-Kromosoeto, E. R. van Wering, D. Reinhardt, M. Horstmann, G. J. L. Kaspers, R. Pieters, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis Blood, April 15, 2008; 111(8): 4322 - 4328. [Abstract] [Full Text] [PDF] F. Dayyani, J. Wang, J.-R. J. Yeh, E.-Y. Ahn, E. Tobey, D.-E. Zhang, I. D. Bernstein, R. T. Peterson, and D. A. Sweetser Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survival Blood, April 15, 2008; 111(8): 4338 - 4347. [Abstract] [Full Text] [PDF] G. J.L. Kaspers and C. M. Zwaan Pediatric acute myeloid leukemia: towards high-quality cure of all patients Haematologica, November 1, 2007; 92(11): 1519 - 1532. [Abstract] [Full Text] [PDF] H. Hasle, T. A. Alonzo, A. Auvrignon, C. Behar, M. Chang, U. Creutzig, A. Fischer, E. Forestier, A. Fynn, O. A. Haas, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study Blood, June 1, 2007; 109(11): 4641 - 4647. [Abstract] [Full Text] [PDF] D. Barbaric, T. A. Alonzo, R. B. Gerbing, S. Meshinchi, N. A. Heerema, D. R. Barnard, B. J. Lange, W. G. Woods, R. J. Arceci, and F. O. Smith Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961 Blood, March 15, 2007; 109(6): 2314 - 2321. [Abstract] [Full Text] [PDF] S. Meshinchi and R. J. Arceci Prognostic Factors and Risk-Based Therapy in Pediatric Acute Myeloid Leukemia Oncologist, March 1, 2007; 12(3): 341 - 355. [Abstract] [Full Text] [PDF] H. Lapillonne, A. Renneville, A. Auvrignon, C. Flamant, A. Blaise, C. Perot, J.-L. Lai, P. Ballerini, F. Mazingue, S. Fasola, et al. High WT1 Expression After Induction Therapy Predicts High Risk of Relapse and Death in Pediatric Acute Myeloid Leukemia J. Clin. Oncol., April 1, 2006; 24(10): 1507 - 1515. [Abstract] [Full Text] [PDF] D. L. Johnston, T. A. Alonzo, R. B. Gerbing, B. J. Lange, and W. G. Woods Risk Factors and Therapy for Isolated Central Nervous System Relapse of Pediatric Acute Myeloid Leukemia J. Clin. Oncol., December 20, 2005; 23(36): 9172 - 9178. [Abstract] [Full Text] [PDF] J. J. Ortega, L. Madero, G. Martin, A. Verdeguer, P. Garcia, R. Parody, J. Fuster, A. Molines, A. Novo, G. Deben, et al. Treatment With All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group J. Clin. Oncol., October 20, 2005; 23(30): 7632 - 7640. [Abstract] [Full Text] [PDF] B. J. Lange, R. B. Gerbing, J. Feusner, J. Skolnik, N. Sacks, F. O. Smith, and T. A. Alonzo Mortality in Overweight and Underweight Children With Acute Myeloid Leukemia JAMA, January 12, 2005; 293(2): 203 - 211. [Abstract] [Full Text] [PDF] M. E. Ross, R. Mahfouz, M. Onciu, H.-C. Liu, X. Zhou, G. Song, S. A. Shurtleff, S. Pounds, C. Cheng, J. Ma, et al. Gene expression profiling of pediatric acute myelogenous leukemia Blood, December 1, 2004; 104(12): 3679 - 3687. [Abstract] [Full Text] [PDF] R. M. Gurevich, P. D. Aplan, and R. K. Humphries NUP98-Topoisomerase I acute myeloid leukemia-associated fusion gene has potent leukemogenic activities independent of an engineered catalytic site mutation Blood, August 15, 2004; 104(4): 1127 - 1136. [Abstract] [Full Text] [PDF] S. de Botton, V. Coiteux, S. Chevret, C. Rayon, E. Vilmer, M. Sanz, J. de La Serna, N. Philippe, A. Baruchel, G. Leverger, et al. Outcome of Childhood Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid and Chemotherapy J. Clin. Oncol., April 15, 2004; 22(8): 1404 - 1412. [Abstract] [Full Text] [PDF] D. G. Gilliland, C. T. Jordan, and C. A. Felix The Molecular Basis of Leukemia Hematology, January 1, 2004; 2004(1): 80 - 97. [Abstract] [Full Text] [PDF] N. Aladjidi, A. Auvrignon, T. Leblanc, Y. Perel, A. Benard, P. Bordigoni, V. Gandemer, I. Thuret, J. H. Dalle, C. Piguet, et al. Outcome in Children With Relapsed Acute Myeloid Leukemia After Initial Treatment With the French Leucemie Aique Myeloide Enfant (LAME) 89/91 Protocol of the French Society of Pediatric Hematology and Immunology J. Clin. Oncol., December 1, 2003; 21(23): 4377 - 4385. [Abstract] [Full Text] [PDF] C. M. Zwaan, S. Meshinchi, J. P. Radich, A. J. P. Veerman, D. R. Huismans, L. Munske, M. Podleschny, K. Hahlen, R. Pieters, M. Zimmermann, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance Blood, October 1, 2003; 102(7): 2387 - 2394. [Abstract] [Full Text] [PDF] C. Schoch, S. Schnittger, M. Klaus, W. Kern, W. Hiddemann, and T. Haferlach AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases Blood, October 1, 2003; 102(7): 2395 - 2402. [Abstract] [Full Text] [PDF] T. Yagi, A. Morimoto, M. Eguchi, S. Hibi, M. Sako, E. Ishii, S. Mizutani, S. Imashuku, M. Ohki, and H. Ichikawa Identification of a gene expression signature associated with pediatric AML prognosis Blood, September 1, 2003; 102(5): 1849 - 1856. [Abstract] [Full Text] [PDF] C. M. Zwaan, G. J. L. Kaspers, R. Pieters, K. Hahlen, D. R. Huismans, M. Zimmermann, J. Harbott, R. M. Slater, U. Creutzig, and A. J. P. Veerman Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities Blood, October 16, 2002; 100(9): 3352 - 3360. [Abstract] [Full Text] [PDF] N. Dastugue, M. Lafage-Pochitaloff, M.-P. Pages, I. Radford, C. Bastard, P. Talmant, M. J. Mozziconacci, C. Leonard, C. Bilhou-Nabera, C. Cabrol, et al. Cytogenetic profile of childhood and adult megakaryoblastic leukemia (M7): a study of the Groupe Francais de Cytogenetique Hematologique (GFCH) Blood, June 28, 2002; 100(2): 618 - 626. [Abstract] [Full Text] [PDF] Y. Perel, A. Auvrignon, T. Leblanc, J.-P. Vannier, G. Michel, B. Nelken, V. Gandemer, C. Schmitt, J.-P. Lamagnere, L. De Lumley, et al. Impact of Addition of Maintenance Therapy to Intensive Induction and Consolidation Chemotherapy for Childhood Acute Myeloblastic Leukemia: Results of a Prospective Randomized Trial, LAME 89/91 J. Clin. Oncol., June 15, 2002; 20(12): 2774 - 2782. [Abstract] [Full Text] [PDF] J. E. Rubnitz, S. C. Raimondi, X. Tong, D. K. Srivastava, B. I. Razzouk, S. A. Shurtleff, J. R. Downing, C.-H. Pui, R. C. Ribeiro, and F. G. Behm Favorable Impact of the t(9;11) in Childhood Acute Myeloid Leukemia J. Clin. Oncol., May 1, 2002; 20(9): 2302 - 2309. [Abstract] [Full Text] [PDF] J. Brown, M. Jawad, S. R. F. Twigg, K. Saracoglu, A. Sauerbrey, A. E. Thomas, R. Eils, J. Harbott, and L. Kearney A cryptic t(5;11)(q35;p15.5) in 2 children with acute myeloid leukemia with apparently normal karyotypes, identified by a multiplex fluorescence in situ hybridization telomere assay Blood, April 1, 2002; 99(7): 2526 - 2531. [Abstract] [Full Text] [PDF] R Nounou, H Al-Zahrani H, D S Ajarim, J Martin, A Iqbal, R Naufal, R Stuart, G Roberts, and M Gyger Extramedullary myeloid cell tumours localised to the mediastinum. A rare clinicopathological entity with unique karyotypic features J. Clin. Pathol., March 1, 2002; 55(3): 221 - 225. [Abstract] [Full Text] [PDF] K. U. Park, D. S. Lee, H. S. Lee, C. J. Kim, and H. I. Cho Granulocytic Sarcoma in MLL-Positive Infant Acute Myelogenous Leukemia : Fluorescence in Situ Hybridization Study of Childhood Acute Myelogenous Leukemia for Detecting MLL Rearrangement Am. J. Pathol., December 1, 2001; 159(6): 2011 - 2016. [Abstract] [Full Text] [PDF] D. A. Sweetser, C.-S. Chen, A. A. Blomberg, D. A. Flowers, P. C. Galipeau, M. T. Barrett, N. A. Heerema, J. Buckley, W. G. Woods, I. D. Bernstein, et al. Loss of heterozygosity in childhood de novo acute myelogenous leukemia Blood, August 15, 2001; 98(4): 1188 - 1194. [Abstract] [Full Text] [PDF] M. L. Slovak, L. Tcheurekdjian, F. F. Zhang, and J. L. Murata-Collins Simultaneous Detection of Multiple Genetic Aberrations in Single Cells by Spectral Fluorescence in Situ Hybridization Cancer Res., February 1, 2001; 61(3): 831 - 836. [Abstract] [Full Text] S. Strehl, M. Konig, G. Mann, and O. A. Haas Multiplex reverse transcriptase-polymerase chain reaction screening in childhood acute myeloblastic leukemia Blood, February 1, 2001; 97(3): 805 - 808. [Abstract] [Full Text] [PDF] M. L. Slovak, K. J. Kopecky, P. A. Cassileth, D. H. Harrington, K. S. Theil, A. Mohamed, E. Paietta, C. L. Willman, D. R. Head, J. M. Rowe, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study Blood, December 15, 2000; 96(13): 4075 - 4083. [Abstract] [Full Text] [PDF]

	Copyright © 1999 by American Society of Hematology         Online ISSN: 1528-0020